Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Operating Leases (2021 - 2026)

TransMedics has reported Operating Leases over the past 5 years, most recently at $3.6 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 42.76% year-over-year to $3.6 million; the TTM value through Dec 2025 reached $3.6 million, down 42.76%, while the annual FY2025 figure was $3.6 million, 42.76% down from the prior year.
  • Operating Leases for Q4 2025 was $3.6 million at TransMedics, down from $4.4 million in the prior quarter.
  • Over five years, Operating Leases peaked at $8.6 million in Q4 2021 and troughed at $3.6 million in Q4 2025.
  • A 5-year average of $6.9 million and a median of $7.2 million in 2024 define the central range for Operating Leases.
  • Biggest five-year swings in Operating Leases: rose 5.71% in 2023 and later crashed 42.76% in 2025.
  • Year by year, Operating Leases stood at $8.6 million in 2021, then decreased by 13.82% to $7.4 million in 2022, then increased by 3.94% to $7.7 million in 2023, then dropped by 18.92% to $6.2 million in 2024, then crashed by 42.76% to $3.6 million in 2025.
  • Business Quant data shows Operating Leases for TMDX at $3.6 million in Q4 2025, $4.4 million in Q3 2025, and $4.9 million in Q2 2025.